A good start to 2024; guidance unchanged

03/05/24 -"Genmab’s Q1 sales exceeded expectations, although profitability fell somewhat short. This robust performance was led by strong growth across all the offerings. Despite the 2024 guidance remaining ..."

Executive summary
Conflict of interest

Pages

Language

English

Published on

03/05/24

Download

You may also be interested by these reports :

21/05/24

Idorsia

Jean-Paul Clozel to step down as CEO

20/05/24

Idea Kicker

BioNTech (Buy, Germany) is a beacon among the much-battered German biotechnology cohort. Founded with venture capital in 2008, the company sits on a ...

17/05/24

Hikma Pharmaceuticals

We have incorporated higher royalty payments in 2024 related to the sale of the generic version of sodium oxybate (medicine to treat symptoms of ...

15/05/24

H Lundbeck

The Q1 results surpassed the consensus estimates, driven by a sustained strong performance from the strategic products. The management nonetheless ...

EXECUTIVE SUMMARY

Updates

Pension Risks

Target & Opinion

Governance & Management

Business & Trends

Graphics : Momentum

Money Making

Graphics : MACD & Volumes

Debt

Graphics : Sensitivities

Valuation

Sector: Performance

DCF

Sector: Key data

NAV/SOTP

Sector: Ratios & Valorisation

Worth knowing

Sector: Peers

Financials

Sector: Analysis

CONFLICTS OF INTEREST

AlphaValue does not have nor seek any business with companies covered in AlphaValue Research paid by subscription. As a result, investors can be confident that there is no conflict of interest that could affect the objectivity of AlphaValue Research.

Corporate broking

Trading in corporate shares

Analyst ownership

Advising of corporate (strategy, marketing, debt, etc)

Research paid for by corporate

Provision of corporate access paid for by corporate

Link between and a banking entity

Brokerage activity at AlphaValue